Looking to expand its genetic medicine portfolio, Lilly has disclosed two strategic collaborations in quick succession. The company entered into a multi-year collaboration with Haya Therapeutics, paying up to US$1 B to leverage Haya’s RNA-guided regulatory genome platform for drug discovery in obesity. The following day, Lilly disclosed its US$409 M partnership with Genetic Leap to leverage the latter’s RNA-targeted artificial intelligence (AI) platform to generate oligonucleotide drugs against selected targets. Both deals align with Lilly’s strategy of making RNA- and DNA-targeting medicines one of the company’s key R&D pillars.